Allergic Contact Dermatitis

Categories: Blood diseases, Immune diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Allergic Contact Dermatitis

MalaCards integrated aliases for Allergic Contact Dermatitis:

Name: Allergic Contact Dermatitis 11 14 63 16 75 31 33
Dermatitis, Allergic Contact 43 71
Allergic Contact Dermatitis Due to Drugs in Contact with Skin 33
Allergic Contact Eczema Due to Food Flavours or Additives 33
Allergic Contact Eczema Due to Plastics or Resin Systems 33
Allergic Contact Eczema Due to Preservatives or Biocides 33
Allergic Contact Eczema Due to Cosmetics or Fragrances 33
Allergic Contact Eczema Due to Hairdressing Products 33
Allergic Contact Eczema Due to Metals or Metal Salts 33
Allergic Contact Eczema Due to Clothing or Footwear 33
Allergic Contact Eczema Due to Systemic Medicaments 33
Allergic Contact Eczema Due to Topical Medicaments 33
Allergic Contact Eczema Due to Dental Materials 33
Allergic Contact Eczema Due to Rubber Chemicals 33
Allergic Contact Dermatitis, Unspecified Cause 33
Allergic Contact Dermatitis Due to Cosmetics 33
Allergic Contact Eczema Due to Proteins 33
Acd - [allergic Contact Dermatitis] 33
Perfume Allergic Contact Dermatitis 33
Contact Dermatitis, Allergic 75
Dermatitis Allergic Contact 53
Allergic Contact Eczema 33
Allergic Dermatitis 33
Allergy Dermatitis 33
Rubber Dermatitis 33
Allergic Eczema 33
Allergy Eczema 33


Summaries for Allergic Contact Dermatitis

PubMed Health : 63 Allergic contact dermatitis: A number of chemical or herbal substances can irritate the skin. Redness, burning or itching are normal skin reactions, for instance, to aggressive cleaning agents. Allergic contact dermatitis (sometimes simply called “contact allergies”) is different, though. Here the immune system overreacts to certain substances – sometimes to very small amounts – that normally wouldn’t cause a reaction. Common examples include certain metals, scents and latex rubber. Contact allergies can lead to severe skin reactions. Unlike with many other kinds of allergies, the reaction doesn’t occur immediately, but after one to three days. And contact allergies develop gradually over a long period of time, as a result of repeated contact with the substance that triggers them. Some people are then no longer able to carry on doing the same kind of work as before.

MalaCards based summary: Allergic Contact Dermatitis, also known as dermatitis, allergic contact, is related to 1,4-phenylenediamine allergic contact dermatitis and palladium allergic contact dermatitis. An important gene associated with Allergic Contact Dermatitis is IL31 (Interleukin 31), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Povidone K30 and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lymph node, and related phenotypes are immune system and respiratory system

Disease Ontology: 11 A contact dermatitis that is an allergic skin reaction to foreign chemical or substances leading to red, itchy, weepy reaction where the skin has come into contact with a substance that the immune system recognizes as foreign.

Wikipedia: 75 Allergic contact dermatitis (ACD) is a form of contact dermatitis that is the manifestation of an... more...

Related Diseases for Allergic Contact Dermatitis

Diseases related to Allergic Contact Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 838)
# Related Disease Score Top Affiliating Genes
1 1,4-phenylenediamine allergic contact dermatitis 33.5 TNF NAT2
2 palladium allergic contact dermatitis 33.3 TNF IL17A IL10
3 chromium allergic contact dermatitis 33.2 IL5 IL4 IL17A IL10
4 irritant dermatitis 32.8 TNF IL4 IL31 IL17A CXCL8 CCL27
5 contact dermatitis 32.7 TNF IL5 IL4 IL31 IL17A IL10
6 dermatitis 32.7 TNF IL5 IL4 IL31 IL17A IL10
7 toxicodendron dermatitis 32.6 TNF SELE ICAM1 CXCL8
8 metal allergy 32.5 TNF IL5 IL4 IL17A IL10
9 cercarial dermatitis 32.0 IL5 IL4
10 dermatitis, atopic 32.0 VCAM1 TNF SELE IL5 IL4 IL31
11 ige responsiveness, atopic 31.7 IL5 IL4 IL10 IFNG
12 exanthem 31.6 TNF IL4 IL17A IL10 IFNG CXCL8
13 urticaria 31.6 TNF SELE IL5 IL4 IL31 IL17A
14 erythema multiforme 31.5 TNF IL5 IL4 IFNG ICAM1 CXCL8
15 alopecia 31.5 TNF IL4 IL17A IFNG
16 allergic disease 31.5 VCAM1 TNF SELE IL5 IL4 IL17A
17 rosacea 31.4 TNF IL17A CXCL8
18 skin disease 31.3 VCAM1 TNF SELE PI3 IL5 IL4
19 acne 31.3 TNF IL17A IL10 DEFB4A CXCL8
20 seborrheic dermatitis 31.3 TNF IL17A DEFB4A CXCL8 CCR6
21 conjunctivitis 31.3 TNF IL5 IL4 IL10 IFNG ICAM1
22 vitiligo-associated multiple autoimmune disease susceptibility 1 31.2 TNF IL17A CCR6
23 pustular psoriasis 31.2 TNF PI3 IFNG
24 alopecia areata 31.2 TNF IL4 IL17A IFNG ICAM1 CXCR3
25 dermatophytosis 31.1 TNF IL17A DEFB4A CCR6
26 pemphigus 31.1 TNF IL4 IL17A IL10
27 mycosis fungoides 31.0 IL5 IL4 IFNG CXCR3 CCR6 CCR4
28 acute generalized exanthematous pustulosis 31.0 IL17A CXCL8
29 lichen planus 31.0 TNF IL4 IL17A IL10 IFNG ICAM1
30 stomatitis 31.0 TNF IL4 IL10 IFNG CXCL8
31 scabies 31.0 IL5 IL4 IL31 CCR6
32 rhinitis 31.0 VCAM1 TNF IL5 IL4 IL17A IL10
33 proteasome-associated autoinflammatory syndrome 1 30.9 VCAM1 TNF SELE IL5 IL4 IL17A
34 herpes zoster 30.9 IL10 IFNG CCR6
35 tetanus 30.9 TNF IL5 IL4 IL10 IFNG
36 skin atrophy 30.9 TNF IL4 IL31
37 acquired immunodeficiency syndrome 30.9 VCAM1 TNF SELE IL10 IFNG ICAM1
38 chronic venous insufficiency 30.9 VCAM1 SELE ICAM1
39 hypereosinophilic syndrome 30.9 IL5 IL4 IL10 IFNG CXCL8
40 chronic ulcer of skin 30.9 TNF DEFB4A CXCL8
41 autoimmune disease 30.9 VCAM1 TNF IL5 IL4 IL17A IL10
42 hidradenitis 30.9 TNF IL17A IFNG
43 hidradenitis suppurativa 30.9 TNF IL17A IFNG
44 fungal infectious disease 30.9 TNF IL5 IL4 IL17A IL10 IFNG
45 chronic urticaria 30.8 SELE IL5 IL31
46 blepharitis 30.8 TNF IL4 IL17A CXCL8 CCR6
47 severe cutaneous adverse reaction 30.8 TNF IFNG CCR6
48 psoriasis 30.8 VCAM1 TNF SELE PI3 IL5 IL4
49 oral lichen planus 30.8 VCAM1 ICAM1
50 type 1 diabetes mellitus 30.7 TNF IL4 IL17A IL10 IFNG ICAM1

Graphical network of the top 20 diseases related to Allergic Contact Dermatitis:

Diseases related to Allergic Contact Dermatitis

Symptoms & Phenotypes for Allergic Contact Dermatitis

MGI Mouse Phenotypes related to Allergic Contact Dermatitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.03 CCL19 CCL22 CCR4 CCR6 CXCR3 DEFB4A
2 respiratory system MP:0005388 9.61 CCR4 CXCR3 IFNG IL10 IL17A IL4
3 hematopoietic system MP:0005397 9.47 CCL19 CCR4 CCR6 CXCR3 DEFB4A ICAM1

Drugs & Therapeutics for Allergic Contact Dermatitis

PubMed Health treatment related to Allergic Contact Dermatitis: 63

Allergic skin reactions are usually treated with steroid creams, ointments or solutions. But the main thing to do is avoid contact with the substance that triggers the reaction. Protective gloves and clothing can help here, for instance. A change of career may have to be considered if it isn’t possible to avoid contact with the substance in the workplace. If you are believed to have a work-related contact allergy , it’s a good idea to have your doctor inform your employer’s liability insurance. The insurance will cover certain costs, like the costs of protective measures, if the allergy is recognized as being work-related.

Drugs for Allergic Contact Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
3 Immunosuppressive Agents Phase 4
4 Immunologic Factors Phase 4
5 Calcineurin Inhibitors Phase 4
Fluticasone Approved, Experimental Phase 2, Phase 3 90566-53-3 4659387 5311101
Betamethasone Approved, Vet_approved Phase 2, Phase 3 378-44-9 9782
Adalimumab Approved, Experimental Phase 2, Phase 3 331731-18-1
Ustekinumab Approved, Investigational Phase 2, Phase 3 815610-63-0
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
Squaric acid dibutyl ester Investigational Phase 2, Phase 3 2892-62-8
13 Bronchodilator Agents Phase 2, Phase 3
14 Anti-Asthmatic Agents Phase 2, Phase 3
15 Adjuvants, Immunologic Phase 2, Phase 3
16 Betamethasone-17,21-dipropionate Phase 2, Phase 3
Betamethasone Valerate Phase 2, Phase 3 2152-44-5
Betamethasone sodium phosphate Phase 2, Phase 3
Betamethasone benzoate Phase 2, Phase 3
20 Xhance Phase 2, Phase 3
21 Anesthetics, Local Phase 2, Phase 3
Triamcinolone hexacetonide Phase 2, Phase 3
Triamcinolone diacetate Phase 2, Phase 3
24 Anesthetics Phase 2, Phase 3
Triamcinolone Acetonide Phase 2, Phase 3 6436
26 Respiratory System Agents Phase 2, Phase 3
27 Analgesics Phase 2, Phase 3
28 Antirheumatic Agents Phase 3
29 Interleukin 1 Receptor Antagonist Protein Phase 3
Apremilast Approved, Investigational Phase 2 608141-41-9 10151715 11561674
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
Bacitracin Approved, Vet_approved Phase 2 1405-87-4 10909430
Parthenolide Approved, Investigational Phase 2 20554-84-1
Nickel Phase 2 7440-02-0 934
35 Anti-Infective Agents Phase 2
36 Phosphodiesterase Inhibitors Phase 2
37 Phosphodiesterase 4 Inhibitors Phase 2
38 Angiogenesis Inhibitors Phase 2
39 Anti-Inflammatory Agents, Non-Steroidal Phase 2
40 Analgesics, Non-Narcotic Phase 2
41 Anti-Infective Agents, Local Phase 2
Prednisolone phosphate Approved, Vet_approved Phase 1 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 1 52-21-1
Prednisolone Approved, Vet_approved Phase 1 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 1 2921-57-5 1875
Methylprednisolone aceponate Approved, Vet_approved Phase 1 86401-95-8 4474933
Methylprednisolone Approved, Vet_approved Phase 1 83-43-2 4159 6741
Prednisolone hemisuccinate Experimental Phase 1 2920-86-7 4897
49 Neuroprotective Agents Phase 1
Methylprednisolone Acetate Phase 1 584547

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
2 Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations Completed NCT01798589 Phase 4 Ethylenediamine dihydrochloride allergen patch
3 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis Completed NCT00667056 Phase 4 tacrolimus ointment;placebo ointment
4 The Effects of Dupilumab on Allergic Contact Dermatitis Recruiting NCT03935971 Phase 4 Dupilumab
5 Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis Unknown status NCT01239719 Phase 3 Dexamethasone + clemastine;Dexamethasone
6 Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering Recruiting NCT05535738 Phase 2, Phase 3 Squaric Acid Dibutyl Ester;Dupilumab;Adalimumab;Ustekinumab;Guselkumab;Canakinumab;Sarilumab;Triamcinolone Acetonide;Betamethasone Valerate;Fluticasone Propionate
7 The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis: A Randomized Controlled Trial With Anakinra vs. Placebo Not yet recruiting NCT05498467 Phase 3 Anakinra;Sodium Chloride 9mg/ml Injection
8 Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis Withdrawn NCT01125761 Phase 3 dexamethasone 0.5 mg and 1.0 mg clemastine cream;Dexamethasone 0,5 mg cream
9 A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm Completed NCT00867607 Phase 1, Phase 2 MRX-6;Steroid
10 A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis Completed NCT00931242 Phase 2 Apremilast
11 Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study Completed NCT00132600 Phase 2 bacitracin (allergen)
12 Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for "TRUE Test® Panel 3" - a Phase II, Dose-Response Study. Completed NCT00133341 Phase 2 Goldnatriomthiosulphate, MDBGN, parthenolide
13 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis Completed NCT00928447 Phase 2 rHuPH20;Placebo
14 A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis Active, not recruiting NCT03680131 Phase 2 EB01 Cream Placebo;EB01 Cream 0.2%;EB01 Cream 1.0%;EB01 Cream 2.0%
15 A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis Completed NCT01244607 Phase 1 Placebo;NI-0801
16 Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects. Completed NCT00141180 Phase 1 CP-481,715
17 Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study). Completed NCT01529320 Phase 1 Adventan® (methylprednisolone aceponate 0,1%)
18 Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation Unknown status NCT00445029
19 Nickel Desensitization Using Topical Therapy Unknown status NCT01413477 Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
20 Real-life Study to Assess the Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk of Dysbiosis During the First Year of Life Unknown status NCT04182425
21 RESTenosis in Patients With Contact ALLergy to Metals Zabrze Study Unknown status NCT03588962
22 Low Dose Exposure to Oxidized R-limonene - A Double Blinded Vehicle Controlled Repeated Open Application Test (ROAT) Study Completed NCT03313232
23 Evaluation of the Clinical Implication of Short Repeated Nickel Exposures Completed NCT03309215
24 Alteration of the microRNA-126 Expression: a Possible Mechanism in Allergic Contact Dermatitis to Nickel Completed NCT04365140
25 Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study Completed NCT03902392
26 Epidemiology and Co-Reactivity of Novel Surfactant Allergens Completed NCT02534441
27 Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II) Completed NCT01797562
28 Analysis of Immune Reactions Occurring Upon Administration of Patch Tests and Contact Dermatitis Affected Skin Completed NCT01546298
29 A Study to Determine if Tetrix Cream Impedes the Resolution of Experimentally Induced Allergic Contact Dermatitis Completed NCT00643214
30 Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma? Completed NCT00693550
31 Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy Completed NCT01953380
32 Children With Aluminium Contact Allergy: Cutaneous Exposure Study Completed NCT04438135
33 Skin Prick Test in Healthy Volunteers of Any Sex, to Investigate the Potential Allergy to NeoMatriXTM Wound Matrix Completed NCT03522675
34 Human Repeated Insult Patch Test Completed NCT03474874
35 Democratization of Allergy Skin Patch Testing to Increase Efficiency and Scale of the Practice Recruiting NCT05339750
36 An Investigator Initiated Study to Evaluate the Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions In Healthy Adult Male Subjects Recruiting NCT03945760 Early Phase 1 Baricitinib;Placebo
37 The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers Recruiting NCT04085705
38 Children With Aluminium Contact Allergy: Oral Exposure Study (the Pancake Study) Recruiting NCT04921163
39 Testing of Alternatives for Dark Hair Dyes in Patients With Proven Sensitization to Para-Phenylenediamine Recruiting NCT04772482
40 Cutaneous and Systemic Reactions to Metal Implants: Utility of Patch Testing Prior and Post Placement of Metal Orthopedic Implants Terminated NCT02483728
41 Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC) Withdrawn NCT04240587

Search NIH Clinical Center for Allergic Contact Dermatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Methdilazine hydrochloride
trimeprazine tartrate

Cochrane evidence based reviews: dermatitis, allergic contact

Genetic Tests for Allergic Contact Dermatitis

Anatomical Context for Allergic Contact Dermatitis

Organs/tissues related to Allergic Contact Dermatitis:

MalaCards : Skin, T Cells, Lymph Node, Eye, Neutrophil, Salivary Gland, Dorsal Root Ganglion

Publications for Allergic Contact Dermatitis

Articles related to Allergic Contact Dermatitis:

(show top 50) (show all 8689)
# Title Authors PMID Year
Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. 53 62
19818069 2010
Filaggrin mutations and allergic contact sensitization. 53 62
18478014 2008
Leukotriene B(4) enhances tumour necrosis factor-alpha-induced CCL27 production in human keratinocytes. 53 62
17581202 2007
Human arylamine N-acetyltransferase 2 polymorphism and susceptibility to allergic contact dermatitis. 53 62
16533241 2006
CCL22-induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first beta-strand of chemokine. 53 62
15714581 2005
Th(1)/Th(2) responses to drugs. 53 62
11164989 2001
IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. 53 62
10903743 2000
Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. 53 62
10886512 2000
The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. 53 62
10504443 1999
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). 53 62
10233762 1999
IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. 53 62
9886425 1999
Interleukin-4 and the interleukin-4 receptor in allergic contact dermatitis. 53 62
9504244 1998
Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. 53 62
9155652 1997
Langerhans' cell expression of the selectin ligand, sialyl Lewis x. 53 62
7512530 1994
4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis. 53 62
8311112 1994
Effect of various metals on intercellular adhesion molecule-1 expression and tumour necrosis factor alpha production by normal human keratinocytes. 53 62
7864660 1994
[Immune mechanisms of atopic dermatitis]. 53 62
7507285 1993
Expression of adhesion molecules in early allergic patch test reactions. 53 62
1638065 1992
Keratinocyte expression of intercellular adhesion molecule 1 (ICAM-1) correlated with infiltration of lymphocyte function associated antigen 1 (LFA-1) positive cells in evolving allergic contact dermatitis reactions. 53 62
1682230 1991
Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. 53 62
1706195 1991
[Allergic contact dermatitis from a new dentin adhesive system]. 53 62
2151486 1990
[Contact dermatitis, due to (di)methacrylates, on the hands of dental personnel]. 53 62
2144665 1990
Expression of intercellular adhesion molecule-1 in murine allergic contact dermatitis. 53 62
1983170 1990
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. 62
36387062 2023
Management of Allergic Skin Disorders in Pregnancy. 62
36410998 2023
Childhood blood eosinophils and symptoms of allergic disorders: a cross-sectional study in Southern China. 62
36259652 2022
Cheilitis caused by allergic contact dermatitis to cinnamon in chai tea: a case report. 62
36461791 2022
Occupational allergic contact dermatitis caused by colophonium, an unsuspected sensitizer in a petrochemical worker. 62
36050864 2022
Allergic contact dermatitis from resacetophenone (2',4'-dihydroxyacetophenone; CAS no. 89-84-9) in an antifungal nail preparation. 62
35980321 2022
Alopecia areata after severe allergic contact dermatitis to a permanent hair dye. 62
35984243 2022
Occupational airborne allergic contact dermatitis to invasive Compositae species treated with abrocitinib: A case report. 62
35980345 2022
T cells in resolved allergic contact dermatitis steer tissue inflammation and MMP-12-driven tissue modulation. 62
35984563 2022
A case of generalized allergic contact dermatitis due to sodium lauroyl methylaminopropionate in a shampoo. 62
36042564 2022
A systematic review of allergic and irritative contact dermatitis of the vulva: the most important allergens/irritants and the role of patch testing. 62
36458568 2022
Protease- and cell type-specific activation of protease-activated receptor 2 in cutaneous inflammation. 62
36161697 2022
Allergic contact dermatitis from vitamins: A systematic review. 62
36210883 2022
Non-occupational allergic contact dermatitis from epoxy resin in children's games. 62
36444522 2022
Topical eye medications causing allergic contact dermatitis. 62
36382619 2022
Allergic contact dermatitis due to excipients in topical drugs. 62
36331181 2022
Pustular Allergic Contact Dermatitis Caused by a Topical Probiotic. 62
36399531 2022
Allergic contact dermatitis caused by herbicide containing glyphosate-isopropylamine salt. 62
36416721 2022
Too Much of a Good Thing? Allergic Contact Dermatitis to Pimecrolimus. 62
35318979 2022
Development of a new hydrogel for the prevention of allergic contact dermatitis. 62
36216166 2022
Isocyanates may contribute to allergic contact dermatitis from diabetes devices and wound dressings. 62
35815495 2022
Bleaching powders, bleaching creams and other hair lightening preparations as sources for (airborne) allergic contact dermatitis and other health effects in hairdressers: Results of an empirical study. 62
36369878 2022
A case of frog egg-like perifollicular allergic contact dermatitis due to hydroquinone. 62
36371774 2022
Assessment of Comorbidities Associated With Allergic Contact Dermatitis in the United States: A Retrospective Claims-Based Study. 62
36255394 2022
Allergic contact dermatitis from pantolactone and dexpanthenol in wound healing creams. 62
35946606 2022
Allergic contact dermatitis to an epidural catheter but what's the allergen?: A case report. 62
35908209 2022
Medical adhesive allergens: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2018. 62
34875303 2022

Variations for Allergic Contact Dermatitis

Expression for Allergic Contact Dermatitis

Search GEO for disease gene expression data for Allergic Contact Dermatitis.

Pathways for Allergic Contact Dermatitis

Pathways related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.89 TNF IL5 IL4 IL17A IL10 CXCR3
Show member pathways
Show member pathways
13.58 TNF IL5 IL4 IL31 IL17A IL10
Show member pathways
13.47 CCL19 CCL22 CCL27 CCR4 CCR6 CXCL8
Show member pathways
13.46 TNF IL5 IL4 IL17A IL10 CXCR3
Show member pathways
Show member pathways
Show member pathways
13.25 TNF IL5 IL4 IL17A IL10 CXCR3
Show member pathways
12.94 CCL19 CCL22 CCL27 CCR4 CCR6 CXCL8
Show member pathways
12.72 TNF IL5 IL4 IL17A IL10 IFNG
13 12.65 VCAM1 TNF IL4 IL17A IL10 IFNG
Show member pathways
Show member pathways
12.24 TNF IL5 IL4 IL17A IL10 IFNG
16 12.15 TNF IL4 IL10 IFNG
17 12.11 TNF IL5 IL4 IL10 IFNG
Show member pathways
12.1 CCL19 CCL22 CCL27 CCR4 CCR6 CXCL8
20 12.01 VCAM1 IL10 CXCL8 CCR6 CCR4
Show member pathways
11.98 TNF IL17A IL10 IFNG
23 11.89 VCAM1 TNF IL4 IL17A IL10 ICAM1
Show member pathways
11.87 IL17A ICAM1 CXCL8
25 11.87 TNF IL4 IL10 IFNG CCL19
Show member pathways
11.86 IL4 IL17A IFNG
27 11.85 IL5 IL4 IL10 IFNG CXCL8
Show member pathways
Show member pathways
11.81 VCAM1 CXCL8 CCL19
30 11.79 VCAM1 TNF IL10 ICAM1 CXCL8
31 11.77 TNF IL5 IL4 CXCL8
Show member pathways
33 11.76 TNF ICAM1 CXCL8
34 11.76 TNF IL10 IFNG
Show member pathways
11.76 TNF IL5 IL4 IL10 IFNG
36 11.73 TNF IL5 IL4 IL17A IL10 IFNG
37 11.72 IL4 IL17A IFNG
39 11.66 IL5 IL4 IL10
41 11.64 CXCL8 IFNG SELE
43 11.59 TNF IL10 CXCL8
44 11.59 TNF IL4 IL10 IFNG
45 11.52 CCL19 CCL22 CXCL8 ICAM1 IL10 TNF
46 11.46 IFNG IL17A IL4 IL5 TNF
47 11.46 IL5 IL4 IL31 IL10 IFNG CCL22
48 11.46 TNF IL5 IL4 IL17A IL10 IFNG
Show member pathways
11.43 TNF IL10 IFNG
50 11.41 TNF IL5 IL4 IL10 IFNG

GO Terms for Allergic Contact Dermatitis

Cellular components related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.28 VCAM1 TNF SELE ICAM1 CXCR3 CCR6
2 plasma membrane GO:0005887 10.28 VCAM1 TNF SELE ICAM1 CXCR3 CCR6
3 extracellular region GO:0005576 10.27 CCL19 CCL22 CCL27 CXCL8 DEFB4A IFNG
4 external side of plasma membrane GO:0009897 9.86 CCR4 CCR6 CXCR3 ICAM1 IL17A SELE
5 extracellular space GO:0005615 9.83 VCAM1 TNF SELE PI3 IL5 IL4

Biological processes related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.38 TNF IL5 IL4 IL31 IL10 IFNG
2 inflammatory response GO:0006954 10.28 TNF SELE IL5 IL17A CXCR3 CXCL8
3 cellular response to tumor necrosis factor GO:0071356 10.24 VCAM1 CXCL8 CCL22 CCL19
4 response to virus GO:0009615 10.22 TNF IFNG CCL22 CCL19
5 cellular response to interleukin-1 GO:0071347 10.15 CCL19 CCL22 CXCL8 IL17A
6 calcium-mediated signaling GO:0019722 10.15 CCR4 CCR6 CXCL8 CXCR3 SELE TNF
7 response to lipopolysaccharide GO:0032496 10.13 VCAM1 TNF SELE IL10
8 cellular response to amyloid-beta GO:1904646 10.12 VCAM1 TNF ICAM1
9 positive regulation of interleukin-12 production GO:0032735 10.12 IL17A IFNG CCL19
10 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.09 TNF IL5 IL10
11 negative regulation of endothelial cell apoptotic process GO:2000352 10.08 ICAM1 IL10 IL4
12 positive regulation of interleukin-1 beta production GO:0032731 10.08 TNF IL17A IFNG CCL19
13 leukocyte cell-cell adhesion GO:0007159 10.07 VCAM1 SELE ICAM1
14 microglial cell activation GO:0001774 10.03 TNF IL4 IFNG
15 chemokine-mediated signaling pathway GO:0070098 10.03 CCL19 CCL22 CCR4 CCR6 CXCL8 CXCR3
16 chemotaxis GO:0006935 10.03 DEFB4A CXCR3 CXCL8 CCR6 CCR4 CCL27
17 positive regulation of osteoclast differentiation GO:0045672 10.01 IFNG IL17A TNF
18 leukocyte tethering or rolling GO:0050901 9.97 VCAM1 TNF SELE
19 neuroinflammatory response GO:0150076 9.95 IL4 IFNG
20 negative regulation of cytokine production involved in immune response GO:0002719 9.93 IL10 TNF
21 positive regulation of mononuclear cell migration GO:0071677 9.93 IL4 TNF
22 positive regulation of MHC class II biosynthetic process GO:0045348 9.93 IFNG IL10 IL4
23 membrane to membrane docking GO:0022614 9.92 VCAM1 ICAM1
24 regulation of isotype switching GO:0045191 9.91 IL4 IL10
25 leukocyte migration involved in inflammatory response GO:0002523 9.91 TNF SELE CCR6
26 leukocyte migration GO:0050900 9.88 TNF SELE ICAM1
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.88 TNF IFNG
28 positive regulation of nitrogen compound metabolic process GO:0051173 9.87 TNF IFNG
29 positive regulation of vitamin D biosynthetic process GO:0060557 9.83 TNF IFNG
30 chronic inflammatory response to antigenic stimulus GO:0002439 9.81 TNF IL10
31 cell chemotaxis GO:0060326 9.8 CCL19 CCL22 CCL27 CCR4 CCR6 CXCR3
32 immune response GO:0006955 9.7 TNF IL5 IL4 IL17A IL10 IFNG

Molecular functions related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C-C chemokine binding GO:0019957 9.8 CXCR3 CCR6 CCR4
2 C-C chemokine receptor activity GO:0016493 9.73 CXCR3 CCR6 CCR4
3 chemokine receptor activity GO:0004950 9.63 CXCR3 CCR6 CCR4
4 cytokine activity GO:0005125 9.58 TNF IL5 IL4 IL31 IL17A IL10
5 chemokine activity GO:0008009 9.56 CCL19 CCL22 CCL27 CXCL8

Sources for Allergic Contact Dermatitis

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....